GIVE Teaming Profiles
This page is designed to help facilitate connections between prospective proposers, which ARPA-H anticipates will be necessary to achieve the goals of the Genetic Medicines and Individualized Manufacturing (GIVE) program. Prospective performers are encouraged (but not required) to form teams with varied technical expertise to submit a proposal.
If either you or your organization are interested in teaming, please create a profile via the ARPA-H Solutions Portal linked below. Your details will then be added to this page, which is publicly available.
Please note that by publishing the teaming profiles list, ARPA-H is not endorsing, sponsoring, or otherwise evaluating the qualifications of the individuals or organizations included here or the accuracies of the statements made therein. Submissions to the teaming profiles list are reviewed and updated periodically.
GIVE Teaming Profiles
To narrow the results in the Teaming Profiles List, please use the input below to filter results based on your search term. The list will filter as you type.
| Xuan Wang | Virginia Tech | xuanw@vt.edu | Blacksburg, VA | We have a recent pitch video on “Towards Intelligent and Resilient U.S. Pharmaceutical Supply Chains via Multi-Agent AI” has been deemed Awardable by the DARPA ERIS Marketplace. | Manufacturing partners | TA1: Automated RNA Manufacturing, TA2: Integrated Quality Control |
| Karen Weisinger | Cell X Technologies | kweisinger@cellxtechnologies.com | Woburn, MA | Cell X brings a fully, automated solution for adherent cell manufacturing, anchored by it's proprietary Celligent system and C-Suite software platform, together enabling low variability and data-rich workflows that enable IND submissions. Using the Celligent, we have a strong track record of generating iPSC cell lines as well as various types of target cells from iPSCs in both research and GMP settings, making our platform especially suitable for the automation portion of the GIVE initiative. | We seek a therapeutic developer partner for the GIVE initiative to automate processes on our system and create reliable therapeutics. Our goal is to collaborate on an innovative therapy that truly benefits from automation, where the synergy of our technologies and expertise is greater than the sum of its parts. | TA2: Integrated Quality Control |
| Karen Weisinger | Cell X Technologies | kweisinger@cellxtechnologies.com | WOBURN, MA | Cell X brings a fully, automated solution for adherent cell manufacturing, anchored by it's proprietary Celligent system and C-Suite software platform, together enabling low variability and data-rich workflows that enable IND submissions. Using the Celligent, we have a strong track record of generating iPSC cell lines as well as various types of target cells from iPSCs in both research and GMP settings, making our platform especially suitable for the automation portion of the GIVE initiative. | We seek a therapeutic developer partner for the GIVE initiative to automate processes on our system and create reliable therapeutics. Our goal is to collaborate on an innovative therapy that truly benefits from automation, where the synergy of our technologies and expertise is greater than the sum of its parts. | TA2: Integrated Quality Control |
| Graham Taylor | Helix Biotech, Inc. | graham@helix-biotech.com | Knoxville, TN | Helix Biotech specializes in custom DNA/RNA synthesis and the development and GMP manufacturing of nucleic acids, lipid nanoparticles (LNPs), liposomes, and hybrid nanoparticles. | Open to teaming for any needs | TA1: Automated RNA Manufacturing, TA2: Integrated Quality Control |
| John Cooke | Houston Methodist Research Institute | jpcooke@houstonmethodist.org | Houston, TX | Our Center for RNA Therapeutics generates fundamental insights in RNA Biology, translating them into transformative therapies for patients. We have novel platforms for circular RNA and more stable mRNA structures with high translational efficiency; and generate AI algorithms for computational RNA biology and therapeutics. Our RNACore synthesizes, purifies, encapsulates, and validates clinical grade mmRNA and circular RNA in ISO7 clean rooms with a cGMP trained team for FDA-approved INDs. | To our knowledge, we are the only AMC capable of generating mmRNA and circular RNA drugs for clinical trials; and have great expertise in synthesis, purification, encapsulation and QC (having made about 600 constructs for about 175 clients; primarily research grade). We are looking for scientists that have expertise in mmRNA-based gene therapy; as well as a medtech company that intends to develop a deployable manufacturing unit for hospital-based personalized mRNA (or circRNA) therapies | TA1: Automated RNA Manufacturing, TA2: Integrated Quality Control |
| Melik Demirel | Penn State University | melikdemirel@gmail.com | university park, PA | high-throughput assays for RNA biomanufacturing | companies or institutes with next generation therapies expertise | TA1: Automated RNA Manufacturing, TA2: Integrated Quality Control |
| Krishanu Saha | University of Wisconsin-Madison | ksaha@wisc.edu | Madison, WI | Developing and clinically implementing innovative RNA-based CRISPR therapies, cancer vaccines, and RNA-modified cell therapies for rare pediatric and adult diseases. | UW-Madison is open to all suggestions for collaboration in this area. | TA1: Automated RNA Manufacturing, TA2: Integrated Quality Control |
| Freddy Nguyen | Nine Diagnostics | freddy.nguyen@ninediagnostics.xyz | Cambridge, MA | Nine Diagnostics develops an AI-enabled nanosensor platform for real-time, in-process quality control in genetic medicine and cell therapy manufacturing. Our carbon-nanotube optical sensors provide rapid, multiplexed proteomic and metabolomic readouts from microliter samples, enabling continuous monitoring of product consistency, cell health, and process stability across distributed biomanufacturing workflows. | We seek partners developing RNA, cell, or gene therapy manufacturing systems who need integrated, automated quality control. Ideal collaborators include bioreactor, process, or analytical platform developers interested in embedding real-time nanosensor feedback to reduce batch variability, accelerate release testing, and enable distributed or on-demand manufacturing. | TA2: Integrated Quality Control, TA1: Automated RNA Manufacturing |
| Minghong Zhong | GeneLancet Biosciences, INC | MINGHONG.ZHONG@genelancetbio.com | Doylestown, PA | GeneLancet (www.genelancetbio.com) advances precision gene editing with its proprietary LgRNA technology. LgRNAs outperform classical guides like sgRNAs and pegRNAs in key areas: superior product quality for enhanced safety, optimized drug-like properties for better delivery, and unmatched scalability for efficient manufacturing. | We seek collaborations in all CRISPR platforms. Check out our guide RNA white paper (https://www.genelancetbio.com/genelancet-guide-rna-white-paper). | TA1: Automated RNA Manufacturing, TA2: Integrated Quality Control |
| Aaron Leopold | NTxBio | aaron.leopold@ntxbio.com | Rio Rancho, NM | NTxBio has an automated and fully-closed benchtop system for continuous flow RNA synthesis and purification. The system produces high-integrity, high-purity mRNA or saRNA up to 11.5+kb and is designed for personalized medicine with instant changeover between constructs. | We seek therapeutic partners as well as upstream DNA synthesis and downstream encapsulation partners to create an integrated end-to-end manufacturing system. | TA1: Automated RNA Manufacturing |
| Marc Taraban | University of Maryland Baltimore | mtaraban@rx.umaryland.edu | Rockville, MD | PAT for noninvasive final product inspection and in-line process monitoring for cell and gene therapy products. Examples include assessing empty/full ratio for viral vector products in gene therapy and cell count and viability in cell therapy. The technology, wNMR, involves no sample preparation and no reagents (e.g., https://pubs.acs.org/doi/10.1021/acs.analchem.1c04088) | Manufacturers of cell and gene therapy products. | TA2: Integrated Quality Control |
| Roger Tang | Triple Ring Technologies | rtang@tripleringtech.com | Newark, CA | Triple Ring Technologies is a leading partner in developing science-driven products across medtech and life sciences. Our interdisciplinary team, including many PhDs, excels in advancing technologies to FDA approval while collaborating with academic researchers. We are currently engaged with ARPA-H on a number of programs. We offer services for development of devices and systems and have direct experience in cell & gene therapy and related quality control diagnostics. We are ISO 13485 certified. | We partner with innovators to solve tough problems and create new businesses. From concept to FDA submission and commercialization, we handle technology development and redesign, as well as complex system integration. We are looking for teaming partners that could use our collaborative assistance to design enabling devices and technologies while navigating the FDA regulatory pathway. We have acted as prime, subcontractor, or vendor on previous submissions. | TA2: Integrated Quality Control, TA1: Automated RNA Manufacturing |
| Mike Valliere | Ribbon Bio | Michael.Valliere@ribbonbiolabs.com | Philadelphia, PA | Ribbon bio is focused on fully automating cell free DNA manufacturing. | We are looking for expertise in QC and CMC for RNA manufacturing. | TA1: Automated RNA Manufacturing |
| Matthew Taylor | University of Colorado Anschutz Medical Campus | matthew.taylor@cuanschutz.edu | Denver, Colorado, CO | Human genetic cardiomyopathies, predominantly dilated and arrhythmogenic; lysosomal storage diseases; rare adult genetic disorders | Our expertise is more on the clinical/translational side; we identify mutation(s) in patients, families, cohorts; we are looking for partners to translate those mutations into targets for rapid therapy development | TA1: Automated RNA Manufacturing |
| Anna Blakney | University of British Columbia | anna.blakney@msl.ubc.ca | Vancouver, BC | We specialize in designing RNA and optimizing manufacturing for large RNA modalities, and have capacity for QC of RNA using sequencing and ddPCR. | Complementary expertise for automated manufacturing and integration of QC. | TA1: Automated RNA Manufacturing |
| Denise Pinson | Medvacon Life Sciences LLC | denise.pinson@medvacon.com | Sparta, NJ | Medvacon is a life sciences consulting firm specializing in quality systems, compliance, and cGMP readiness for regulated environments. Our work centers on designing and implementing quality management systems, leading technology transfers, and ensuring inspection readiness through robust validation and audit processes. We provide deep expertise in laboratory systems, including method validation, instrument qualification, CSV, regulatory documentation, training and remediation support. | Within a teaming relationship, Medvacon would serve as the compliance and quality oversight partner, leading efforts in validation, QA integration, risk management, and regulatory readiness. We would ensure that analytical methods, automated systems, and digital platforms meet FDA, ICH, and GMP standards, helping translate technical innovations into reliable, audit-ready, and scalable QC frameworks aligned with the goals of the GIVE TA2 initiative. | TA2: Integrated Quality Control |
| Balaji Sitharaman | Millennial Scientific | balaji@millennialscientific.com | Stony Brook, NY | We are developing 3D-printed stationary phase materials for the integrated extraction and pre-fractionation of target RNA from other biomacromolecules, followed by separation for downstream quality testing or purification for production. This technology aims to be suitable for distributed manufacturing, economical, and efficient, while minimizing reagent use and footprint. It will also integrate with upstream lysate preparation and downstream sensors for further quality testing or purification. | - We are seeking potential partners who are developing Cell-free RNA manufacturing platforms that require downstream integrated extraction and separation of RNA, either for quality analysis or scale-up purification. -We are also seeking partners that develop or provide bioprocess extraction and separation instrumentation, including pumps for fluid flow, and analytical detectors. | TA2: Integrated Quality Control |
| Jessica Bishop | Ceria Therapeutics | jessica.bishop@ceriatx.com | San Juan, PR | Ceria manufactures small batch bespoke synthetic novel RNA. The company's focus includes RNA modulation of inflammatory pathways, nanoparticle formulation science, and translational research integrating RNA design, proprietary nanoparticle delivery, and in-house manufacturing. | Seek collaboration partners with expertise in synthetic RNA design and synthetic RNA analog manufacturing/synthesis. | TA1: Automated RNA Manufacturing, TA2: Integrated Quality Control |
| Baley Reeves | The National Center for Therapeutics Manufacturing | baley@tamu.edu | College Station, TX | The National Center for Therapeutics Manufacturing (NCTM) is a contract research organization that supports process development and scale up for therapeutic modalities. We have mRNA capabilities up to 5g/day scale with the automated Quantoom Midi system onsite, as well as platformsprocesses for pDNA production, mRNA manufacturing from 1mg-5g scale, and LNP formulation. | QC Assay development, Quality Systems, Regulatory Affairs | TA1: Automated RNA Manufacturing, TA2: Integrated Quality Control |
| Paul OSullivan | Skellig | paul.osullivan@skellig.com | Center Valley, PA | Skellig Manufacturing develops the Internet of Medicine (IoM) — a digital operating system for biomanufacturing that connects process equipment, analytics, and regulatory oversight into one real-time network. Our current focus is automating RNA manufacturing and inline quality verification through IoM-enabled skids that allow therapies to be made locally and validated globally. | Skellig seeks partners with expertise in automated RNA process hardware, single-use flow paths, and inline analytical modules to co-develop a point-of-care manufacturing system under GIVE. We are teamed with Verdot Biotechnologies for skid design and fabrication and welcome collaborators in QC analytics, formulation, and regulatory systems integration. | TA1: Automated RNA Manufacturing, TA2: Integrated Quality Control |
| Arye Lipman | Biosphere | arye@biosphere.io | Oakland, CA | Biosphere has developed UV sterilized biomanufacturing systems for production of a wide array of biotech products. These highly automated, modular units have operational advantages over single-use / steam sterilized, and may be field deployed for use at point of need. We have a team of engineers and scientists developing biomanufacturing infrastructure both upstream and downstream to address urgent natsec needs. | Biosphere's bioreactor platform is flexible and process agnostic - we are looking for partners with a particular bioproduct of interest who would like to manufacture using our systems (or co-develop new systems) to address the needs of ARPA-H or other federal agencies. | TA1: Automated RNA Manufacturing |
| Guillaume Roelandts | Quantoom Biosciences | g.roelandts@quantoom.com | 11 Rue de la Maitrise, 1400 Nivelles, Walloon Brabant, Belgium | Quantoom Biosciences develops the N-FORCE toolbox to enable streamlined m(sa)RNA drug development. This includes Ncode for template design, Ntensify® for RNA synthesis, and Ncapsulate® for delivery. Our integrated, modular platform supports applications from early research to GMP manufacturing, addressing both therapeutic and vaccine needs | Quantoom seeks partners with complementary capabilities in synthetic DNA (e.g., enzymatic synthesis, DNA circularization,...) and advanced Process Analytical Technologies (PAT) to enhance quality control, automation, and real-time monitoring of RNA production. Expertise in AI-driven optimization, microfluidics, or inline analytics would further strengthen the collaboration | TA1: Automated RNA Manufacturing, TA2: Integrated Quality Control |